Alessandro Malagoli

Dr. Alessandro Malagoli

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Federica IlardiFederica Ilardi
Federica Ilardi
Antonello D'AndreaAntonello D'Andrea
Antonello D'Andrea
Flavio D'AscenziFlavio D'Ascenzi
Flavio D'Ascenzi
FBFrancesco Bandera
Francesco Bandera
GBGiovanni Benfari
Giovanni Benfari
O(on behalf of the Working Group of Echocardiography of the Italian Society of Cardiology (SIC)
on behalf of the Working Group of Echocardiography of the Italian Society of Cardiology (SIC)
Left ventricular (LV) global longitudinal strain (GLS) has established itself in the last decade as a reliable, more objective method for the evaluation of LV systolic function, able to detect subtle abnormalities in LV contraction even in the presence of preserved ejection fraction (EF). However, recent studies have demonstrated that GLS, similar to LV EF, has important load dependency. Non-invasive myocardial work (MW) quantification has emerged in the last years as an alternative tool for myocardial function assessment. This new method, incorporating measurement of strain and LV pressure, has shown to overcome GLS and LV EF limitations and provide a loading-independent evaluation of myocardial performance. The presence of a commercially available echocardiographic software for the non-invasive MW calculation has allowed the application of this new method in different settings. This review sought to provide an overview on the current knowledge of non-invasive MW estimation, showing its potential applications and possible added value in clinical practice.

1 February 2019 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
AMAlessandro Malagoli
Alessandro Malagoli
LRLuca Rossi
Luca Rossi
FBFrancesca Bursi
Francesca Bursi
AZAlessia Zanni
Alessia Zanni
CSConcetta Sticozzi
Concetta Sticozzi
GVGiovanni Quinto Villani
Giovanni Quinto Villani

17 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EPEugenio Picano
Eugenio Picano
QCQuirino Ciampi
Quirino Ciampi
LCLauro Cortigiani
Lauro Cortigiani
AAAdelaide M. Arruda-Olson
Adelaide M. Arruda-Olson
Clarissa Borguezan DarosClarissa Borguezan Daros
Clarissa Borguezan Daros
T(The Stress Echo 2030 Study Group of the Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI)
The Stress Echo 2030 Study Group of the Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI)
With stress echo (SE) 2020 study, a new standard of practice in stress imaging was developed and disseminated: the ABCDE protocol for functional testing within and beyond CAD. ABCDE protocol was the fruit of SE 2020, and is the seed of SE 2030, which is articulated in 12 projects: 1-SE in coronary artery disease (SECAD); 2-SE in diastolic heart failure (SEDIA); 3-SE in hypertrophic cardiomyopathy (SEHCA); 4-SE post-chest radiotherapy and chemotherapy (SERA); 5-Artificial intelligence SE evaluation (AI-SEE); 6-Environmental stress echocardiography and air pollution (ESTER); 7-SE in repaired Tetralogy of Fallot (SETOF); 8-SE in post-COVID-19 (SECOV); 9: Recovery by stress echo of conventionally unfit donor good hearts (RESURGE); 10-SE for mitral ischemic regurgitation (SEMIR); 11-SE in valvular heart disease (SEVA); 12-SE for coronary vasospasm (SESPASM). The study aims to recruit in the next 5 years (2021–2025) ≥10,000 patients followed for ≥5 years (up to 2030) from ≥20 quality-controlled laboratories from ≥10 countries. In this COVID-19 era of sustainable health care delivery, SE2030 will provide the evidence to finally recommend SE as the optimal and versatile imaging modality for functional testing anywhere, any time, and in any patient.

11 January 2022 in European Journal of Heart Failure
Verified
Journal Article
Closed access
PDF file
AMAlessandro Malagoli
Alessandro Malagoli
LRLuca Rossi
Luca Rossi
AZAlessia Zanni
Alessia Zanni
CSConcetta Sticozzi
Concetta Sticozzi
MPMassimo F. Piepoli
Massimo F. Piepoli
GBGiovanni Benfari
Giovanni Benfari

5 August 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
QCQuirino Ciampi
Quirino Ciampi
FAFrancesco Antonini-Canterin
Francesco Antonini-Canterin
ABAndrea Barbieri
Andrea Barbieri
ABAgata Barchitta
Agata Barchitta
FBFrank Benedetto
Frank Benedetto
S(SIECoVId Study Group, on Behalf of the Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI)
SIECoVId Study Group, on Behalf of the Italian Society of Echocardiography and Cardiovascular Imaging (SIECVI)
Background: Cardiology divisions reshaped their activities during the coronavirus disease 2019 (COVID-19) pandemic. This study aimed to analyze the organization of echocardiographic laboratories and echocardiography practice during the second wave of the COVID-19 pandemic in Italy, and the expectations for the post-COVID era. Methods: We analyzed two different time periods: the month of November during the second wave of the COVID-19 pandemic (2020) and the identical month during 2019 (November 2019). Results: During the second wave of the COVID-19 pandemic, the hospital activity was partially reduced in 42 (60%) and wholly interrupted in 3 (4%) echocardiographic laboratories, whereas outpatient echocardiographic activity was partially reduced in 41 (59%) and completely interrupted in 7 (10%) laboratories. We observed an important change in the organization of activities in the echocardiography laboratory which reduced the operator-risk and improved self-protection of operators by using appropriate personal protection equipment. Operators wore FFP2 in 58 centers (83%) during trans-thoracic echocardiography (TTE), in 65 centers (93%) during transesophageal echocardiography (TEE) and 63 centers (90%) during stress echocardiography. The second wave caused a significant reduction in number of echocardiographic exams, compared to November 2019 (from 513 ± 539 to 341 ± 299 exams per center, −34%, p < 0.001). On average, there was a significant increase in the outpatient waiting list for elective echocardiographic exams (from 32.0 ± 28.1 to 45.5 ± 44.9 days, +41%, p < 0.001), with a reduction of in-hospital waiting list (2.9 ± 2.4 to 2.4 ± 2.0 days, −17%, p < 0.001). We observed a large diffusion of point-of-care cardiac ultrasound (88%), with a significant increase of lung ultrasound usage in 30 centers (43%) during 2019, extended to all centers in 2020. Carbon dioxide production by examination is an indicator of the environmental impact of technology (100-fold less with echocardiography compared to other cardiac imaging techniques). It was ignored in 2019 by 100% of centers, and currently it is considered potentially crucial for decision-making in cardiac imaging by 65 centers (93%). Conclusions: In one year, major changes occurred in echocardiography practice and culture. The examination structure changed with extensive usage of point-of-care cardiac ultrasound and with lung ultrasound embedded by default in the TTE examination, as well as the COVID-19 testing.

21 December 2021 in European Heart Journal Open
Verified
Journal Article
Open access
PDF file
Maria Concetta PastoreMaria Concetta Pastore
Maria Concetta Pastore
Giulia Elena MandoliGiulia Elena Mandoli
Giulia Elena Mandoli
AGAlberto Giannoni
Alberto Giannoni
GBGiovanni Benfari
Giovanni Benfari
FDFrank Dini
Frank Dini
SMSimona Mega
Simona Mega
This sub-study deriving from a multicentre Italian register [Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry (DISCOVER)-ARNI] investigated whether sacubitril/valsartan in addition to optimal medical therapy (OMT) could reduce the rate of implantable cardioverter-defibrillator (ICD) indications for primary prevention in heart failure with reduced ejection fraction (HFrEF) according to European guidelines indications, and its potential predictors. In this observational study, consecutive patients with HFrEF eligible for sacubitril/valsartan from 13 Italian centres were included. Lack of follow-up or speckle tracking data represented exclusion criteria. Demographic, clinical, biochemical, and echocardiographic data were collected at baseline and after 6 months from sacubitril/valsartan initiation. Of 351 patients, 225 (64%) were ICD carriers and 126 (36%) were not ICD carriers (of whom 13 had no indication) at baseline. After 6 months of sacubitril/valsartan, among 113 non-ICD carriers despite having baseline left ventricular (LV) ejection fraction (EF) ≤ 35% and New York Heart Association (NYHA) class = II–III, 69 (60%) did not show ICD indications; 44 (40%) still fulfilled ICD criteria. Age, atrial fibrillation, mitral regurgitation > moderate, left atrial volume index (LAVi), and LV global longitudinal strain (GLS) significantly varied between the groups. With receiver operating characteristic curves, age ≥ 75 years, LAVi ≥ 42 mL/m2 and LV GLS ≥−8.3% were associated with ICD indications persistence (area under the curve = 0.65, 0.68, 0.68, respectively). With univariate and multivariate analysis, only LV GLS emerged as significant predictor of ICD indications at follow-up in different predictive models. Sacubitril/valsartan may provide early improvement of NYHA class and LVEF, reducing the possible number of implanted ICD for primary prevention in HFrEF. Baseline reduced LV GLS was a strong marker of ICD indication despite OMT. Early therapy with sacubitril/valsartan may save infective/haemorrhagic risks and unnecessary costs deriving from ICDs. Sacubitril/valsartan saved 60% of patients with heart failure with reduced ejection fraction (HFrEF) and without ICD [despite having LVEF ≥ 35% and New York Heart Association (NYHA) class II–III at baseline] from implantable cardioverter-defibrillator (ICD) indication after 6 months of therapy.